Lung Cancer

Conference Coverage

Dacomitinib boosts PFS in advanced NSCLC

CHICAGO – In a phase III trial, the dacomitinib arm had triple the PFS rate of the gefitinib arm (30.6% versus 9.6%) at 2 years.

Conference Coverage

Lung cancer linked to suicide

WASHINGTON – A cardiothoracic surgeon presents the differences in suicide rates among U.S. patients living with various kinds of cancer.

Conference Coverage

Alectinib in ALK+ NSCLC is a watershed moment

CHICAGO – In what’s being hailed as practice-changing findings, the anaplastic lymphoma kinase inhibitor alectinib (Alecensa) was associated with...

Pages